Resmetirom and beyond: A new era in MASLD therapeutics

Authors’ contributions

Tejona Johnson-Moore: Writing - original draft, Conceptuali-zation. Dasia Simmons: Writing - original draft, Conceptualiza-tion. Alvina Okafor: Writing - original draft, Conceptualization. D'Era Washington: Writing - original draft, Conceptualization. Padmamalini Baskaran: Writing - review & editing, Writing -original draft, Supervision, Investigation, Funding acquisition, Conceptualization.

Declaration of competing interest

The authors declare that they have no conflict of interest.

Acknowledgements

This work was supported by Howard University Center for Women, Gender and Global Leadership (HUCWGGL) Summer Research grant 2022 to Dr. Padmamalini Baskaran. The content of this paper is solely the responsibility of the authors and does not represent official views of the HUCWGGL.

References

[1] Chiang JYL. New drug therapies for metabolic dysfunction-associated steato-hepatitis. Liver Res. 2025; 9:94-103. https://doi.org/10.1016/j.livres.2025.01.001.

[2] Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus state-ment on new fatty liver disease nomenclature. J Hepatol. 2023; 79:1542-1556. https://doi.org/10.1016/j.jhep.2023.06.003.

[3] Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023; 77: 1335-1347. https://doi.org/10.1097/hep.0000000000000004.

[4] Longo M, Meroni M, Paolini E, et al. TM6SF2/PNPLA3/MBOAT7 loss-of-function genetic variants impact on NAFLD development and progression both in pa-tients and in in vitro models. Cell Mol Gastroenterol Hepatol. 2022; 13: 759-788. https://doi.org/10.1016/j.jcmgh.2021.11.007.

[5] Guirguis E, Dougherty J, Thornby K, Grace Y, Mack K. Resmetirom: the first food and drug Administration-approved medication for nonalcoholic steato-hepatitis (NASH). Ann Pharmacother. 2025; 59:162-173. https://doi.org/10.1177/10600280241259528.

[6] Karim G, Bansal MB. Resmetirom: an orally administered, smallmolecule, liver-directed, β-selective THR agonist for the treatment of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. REV Endocrinol. 2023; 19: 60-70. https://doi.org/10.17925/ee.2023.19.1.60.

[7] Harrison SA, Bedossa P, Guy CD, et al. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. N Engl J Med. 2024; 390:497-509. https://doi.org/10.1056/NEJMoa2309000.

[8] Powell EE. A new treatment and updated clinical practice guidelines for MASLD. Nat Rev Gastroenterol Hepatol. 2025; 22:88-89. https://doi.org/10.1038/s41575-024-01014-y.

[9] Saeed A, Rai KD, Saeed M. Resmetirom: breakthrough therapeutic approach for metabolic dysfunction-associated steatohepatitis. Liver Res. 2024; 8: 193-194. https://doi.org/10.1016/j.livres.2024.07.002.

[10] Sven MF, Pierre B, Manal FA, et al. A randomised, double-blind, placebo-controlled multi-centre, dose-range, proof-of-concept, 24-week treatment study of lanifibranor in adult subjects with non-alcoholic steatohepatitis: design of the NATIVE study. Contemp Clin Trials. 2020; 98:106170. https://doi.org/10.1016/j.cct.2020.106170.

[11] Sanyal AJ, Newsome PN, Kliers I, et al. Phase 3 trial of semaglutide in meta-bolic dysfunction-associated steatohepatitis. N Engl J Med. 2025; 392: 2089-2099. https://doi.org/10.1056/NEJMoa2413258.

[12] Loomba R, Sanyal AJ, Kowdley KV, et al. Randomized, controlled trial of the FGF 21 analogue pegozafermin in NASH. N Engl J Med. 2023; 389:998-1008. https://doi.org/10.1056/NEJMoa2304286.

[13] Hu Y, Sun C, Chen Y, Liu YD, Fan JG. Pipeline of new drug treatment for non-alcoholic fatty liver disease/metabolic dysfunction-associated steatotic liver disease. J Clin Transl Hepatol. 2024; 12:802-814. https://doi.org/10.14218/jcth.2024.00123.

[14] Yang YY, Xie L, Zhang NP, Zhou D, Liu TT, Wu J. Updates on novel pharmaco-therapeutics for the treatment of nonalcoholic steatohepatitis. Acta Pharmacol Sin. 2022; 43:1180-1190. https://doi.org/10.1038/s41401-022-00860-3.

[15] Chadha N, Sterling RK. A clinical review of noninvasive tests for hepatic fibrosis. Gastroenterol Hepatol (N Y). 2024; 20:322-329.